SAN DIEGO, March 16, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today confirmed that a recently issued patent (US patent number 7,776,007) which covers the Company's branded migraine treatment, SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System, has been listed in the United States Food and Drug Administration (FDA) Orange Book. The listed patent describes essential elements of the DosePro technology that enable a patient to prepare the product for administration in a few simple steps. This patent is not expected to expire until 2025, eight years after any of the previous listed patents for SUMAVEL DosePro.
Zogenix launched SUMAVEL DosePro in the United States in January 2010, for the acute treatment of migraine and cluster headache with its co-promotion partner Astellas Pharma US, Inc. SUMAVEL DosePro offers fast-acting, easy-to-use, needle-free subcutaneous administration of sumatriptan in a pre-filled, single-use delivery system. The combination of these unique product attributes allows physicians to prescribe SUMAVEL DosePro to address important unmet needs of many migraine sufferers.
About the FDA Orange BookThe FDA's Approved Drug Products List with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book, lists all drug products that have been approved by the FDA for safety and effectiveness. The Orange Book also includes information on patents which claim an approved drug product or method of use of the drug product, to facilitate the legal requirement that generic drug applicants include an appropriate certification to each such patent as part of any Abbreviated New Drug Application (ANDA) for a generic version of a listed drug. About SUMAVEL DosePro SUMAVEL DosePro (sumatriptan injection) is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache episodes.